Tarsus officer plans $431K stock sale

An officer associated with Tarsus Pharmaceuticals, Inc. has filed a Rule 144 notice to sell 5,387 shares of common stock, following recent sales and prior open market purchases.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) has a notice of proposed sale of common stock filed for the account of officer Elizabeth Yeu-Lin under Rule 144. The filing lists a proposed sale of 5,387 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $430,960.00, based on a market for the shares on NASDAQ as of September 2, 2026. Shares of Tarsus Pharmaceuticals, Inc. outstanding are stated as 43,882,996 as of that date; this is a baseline figure, not the amount being sold.

The notice also reports that during the past three months, 4,601 shares of Tarsus common stock were sold on September 1, 2026 for $339,829.86. Earlier acquisitions of the securities to be sold include open market purchases of 2,377 shares on August 15, 2023 and 3,010 shares on September 14, 2022.

Key Figures

Shares proposed to be sold: 5,387 shares Aggregate market value of shares to be sold: $430,960.00 Shares outstanding: 43,882,996 shares +4 more

7 metrics

Shares proposed to be sold 5,387 shares Common stock proposed for sale under Rule 144

Aggregate market value of shares to be sold $430,960.00 Market value of 5,387 shares of common stock

Shares outstanding 43,882,996 shares Common shares outstanding as of September 2, 2026

Shares sold in past three months 4,601 shares Common shares sold on September 1, 2026

Proceeds from recent sale $339,829.86 Value of 4,601 shares sold on September 1, 2026

Shares purchased August 15, 2023 2,377 shares Open market purchase for cash

Shares purchased September 14, 2022 3,010 shares Open market purchase for cash

Key Terms

Rule 144, Open Market Purchase, aggregate market value, Securities To Be Sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 08/15/2023 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

aggregate market value financial

"Common | Fidelity Brokerage Services LLC ... | 5387 | 430960.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Securities To Be Sold regulatory

"144: Securities To Be Sold"

FAQ

What does the Form 144 filing disclose for TARS?

It discloses that 5,387 shares of Tarsus Pharmaceuticals, Inc. common stock may be sold for an aggregate market value of $430,960.00, with the shares to be sold through Fidelity Brokerage Services LLC on NASDAQ, subject to Rule 144 conditions.

Who is the security holder in the TARS Form 144 filing?

The filing is made for the account of Elizabeth Yeu-Lin, identified as an officer of Tarsus Pharmaceuticals, Inc., with Fidelity Brokerage Services LLC acting as broker and attorney-in-fact signing on her behalf.

How many TARS shares are outstanding according to this Form 144?

The notice states that 43,882,996 shares of Tarsus Pharmaceuticals, Inc. common stock are outstanding as of September 2, 2026, which serves as context for the relative size of the proposed sale.

What TARS share sales occurred in the last three months?

The filing reports that 4,601 shares of Tarsus common stock were sold on September 1, 2026 for a total of $339,829.86, and this transaction is included in the Rule 144 disclosure of securities sold during the past three months.

When and how were the TARS shares being sold under Form 144 acquired?

The notice identifies prior open market purchases from the issuer: 2,377 shares acquired on August 15, 2023 and 3,010 shares acquired on September 14, 2022, both for cash.

On which market are the TARS shares in this Form 144 traded?

The filing lists the market for the Tarsus Pharmaceuticals, Inc. common stock covered by the notice as NASDAQ, with the broker identified as Fidelity Brokerage Services LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 03:39 PM Accepted by SEC EDGAR 09/02/2026 - 03:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001842190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Lin Elizabeth Yeu
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5387	430960.00	43882996	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2023	Open Market Purchase	Issuer			2377	08/15/2023	Cash
Common	09/14/2022	Open Market Purchase	Issuer			3010	09/14/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/01/2026	4601	339829.86

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)